- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01798368
PBASE-system Safety and Tolerability Clinical Investigation
July 1, 2013 updated by: Chordate Medical
An Open Label Study to Evaluate the Safety and Tolerability of Nasal Stimulation Using the PBASE System in Non-patient Volunteers
The purpose of this study is to demonstrate that the treatment does not cause any clinically significant effects that would put patients at risk.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Willing and able to provide written informed consent prior to participation in the clinical investigation
- Judged by the Investigator as suitable for participation in the study without safety concerns based on medical history, physical examination and laboratory results
- Age: 18-65 years of age.
- Gender: Male or female subjects.
- Negative urine drug screen (amphetamine, benzodiazepines, cocaine, marijuana, metamphetamine, morphine) at screening and Visit 2.
- Female subjects have to be post-menopausal for more than one year or use a highly efficient method of contraception (i.e. a method with less than 1% failure rate [e.g. sterilisation, hormone implants, hormone injections, some intrauterine devices, abstinence, or vasectomised partner]). Oral contraceptives: combined pill (estrogen / progestin) and medium-dose progestin pill (for example desogestrel 75ug) are accepted only in combination with the partner using condoms.
- Willing and able to comply with all study procedures and restrictions
Exclusion Criteria:
- A diagnosis of asthma or chronic obstructive pulmonary disorder.
- Ongoing respiratory infection including the nasal cavity.
- Current malignancy of any kind.
- History of frequent nose bleeds or a condition that increases the risk of excessive bleeding.
- Pronounced anterior septal deviation or other significant nasal pathology.
- Known allergy to polyvinylchloride or medicinal liquid paraffin.
- Ongoing treatment with drugs indicated for respiratory or cardiac disorders.
- Any disease, condition (medical or surgical) including allergic, immunological and gastro-intestinal conditions and/or chronic medications which, in the opinion of the investigator, might compromise the study results, or would place the subject at increased risk.
- Vital signs with clinically significant deviations that would make the subject unsuitable for the study, as judged by the investigator.
Evidence of significant cardiovascular disease defined by the following:
- New York Heart Association (NYHA) Class III or IV heart failure;
- Presence of symptomatic coronary artery disease or unstable angina;
- Persistent arrhythmia requiring chronic pharmacotherapy or implantable device;
- Clinically significant abnormalities seen on the screening electrocardiogram as assessed by the investigator;
- Clinically significant deviations in, hematology (including coagulation parameters aPTT and INR) variables, blood chemistry variables or urinalysis as assessed by the investigator.
- Positive screening test for HIV or hepatitis B or C
- Positive alcohol breath test at Visit 1 or at Visit 2.
- Non-smoker since at least six months at time of screening.
- Is currently implanted with an electrical and/or neurostimulator device, including but not limited to cardiac pacemaker, defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant.
- Previously treated with radiation on the face
- Previous radiation therapy to the head or neck regions
- Previously treated with an implantable stimulator or any implantable device in the head and / or neck
- Has a recent or repeated history of syncope.
- Has a recent or repeated history of seizures.
- Surgery within the past three months, determined by the PI to be clinically relevant.
- Strenuous exercise within 2 days of Visit 1 or Visit 2.
- Women who are pregnant or nursing.
- Female subjects: unwilling to use adequate contraceptive measures from the signing of the informed consent until end of the study at the follow-up visit.
- Received study drug in a clinical trial for an investigational drug within the previous 30 days, or 5 half-lives, whichever is longer.
- Blood donation or loss of whole blood exceeding 100 mL within 30 days from screening or plasma within 14 days from screening.
- Excessive intake of alcohol, defined as an average daily intake of greater than three units, or a maximum weekly intake of greater than 21 units ((three units equal 250 ml of 12% alcohol by unit wine).
- Concurrent condition or risk of non-compliance that, in the investigator's opinion, may affect the interpretation of performance or safety data or which otherwise contraindicates participation in a clinical investigation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PBASE system 2.0
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in ECG variables
Time Frame: Approximately 1 hour prior to treatment initiation to 3 hours post treatment termination
|
ECG variables as documented on continuous recording include heart rate, heart rate variability,T-wave morphology, and occurrence of arrhythmias
|
Approximately 1 hour prior to treatment initiation to 3 hours post treatment termination
|
Change in Vital signs
Time Frame: Approximately 1 hour prior to treatment initiation, right before treatment initiation, 10 min after treatment termination and 3 hours after treatment termination
|
Vital signs measurements include blood pressure, pulse and respiratory rate
|
Approximately 1 hour prior to treatment initiation, right before treatment initiation, 10 min after treatment termination and 3 hours after treatment termination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2013
Primary Completion (Actual)
April 1, 2013
Study Registration Dates
First Submitted
February 19, 2013
First Submitted That Met QC Criteria
February 21, 2013
First Posted (Estimate)
February 25, 2013
Study Record Updates
Last Update Posted (Estimate)
July 2, 2013
Last Update Submitted That Met QC Criteria
July 1, 2013
Last Verified
July 1, 2013
More Information
Terms related to this study
Other Study ID Numbers
- PS002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-patient Volunteers
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedEvaluation of Patient Functionality and Utility of Web-Based Personal Health History and Risk AssessCancer | Cancer Screening Patients | Patient VolunteersUnited States
-
Hospital General de Niños Pedro de ElizaldeCompletedNo-Show Patients | Non-Attendance, Patient
-
National Institute on Aging (NIA)RecruitingHealthy Volunteers | Non-Healthy/Non-Frail | FrailUnited States
-
Memorial Sloan Kettering Cancer CenterSusan G. Komen Breast Cancer Foundation; Jewish Home & Hospital Lifecare System and other collaboratorsCompletedNon-cancer Affected VolunteersUnited States
-
Helsinn Healthcare SACompletedHealthy Volunteers | Non-smokersUnited States
-
BeiGeneCompletedHealthy Volunteers: Asian, Non-AsianUnited States
-
Centre for the AIDS Programme of Research in South...Columbia UniversityCompletedPatient Non-complianceSouth Africa
-
Helsinn Healthcare SACelerionCompletedHealthy Volunteers | Non-smokers | Moderate to Heavy SmokersUnited States
-
AstraZenecaQuintiles, Inc.CompletedPart A Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 Years. | Part B Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 and Elderly Volunteers Aged 60 to 80United Kingdom
-
University of Southern CaliforniaCompletedNon-disabled Volunteers | Lacking Voluntary Control of Ear MusclesUnited States
Clinical Trials on PBASE system 2.0
-
Chordate MedicalTerminated
-
Chordate MedicalCompleted
-
Halmstad County HospitalCompletedNon-allergic Rhinitis.Sweden
-
University of Kansas Medical CenterNational Institute of Mental Health (NIMH); Children's Mercy Hospital Kansas... and other collaboratorsCompletedHIVUnited States, Kenya
-
SpectralMDBaylor Research InstituteTerminatedPeripheral Arterial Disease | Amputation WoundUnited States
-
Work Life HelpNational Institute on Aging (NIA)Active, not recruitingPsychosocial Deprivation | Work-Related Stress | Life-work ImbalanceUnited States
-
BrainQ Technologies Ltd.Completed
-
Medtronic CardiovascularCompleted
-
University of Michigan Rogel Cancer CenterDepartment of Health and Human ServicesRecruitingHematologic DiseasesUnited States
-
Aarhus University HospitalNot yet recruitingPatella DysplasiaDenmark